Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - ... 8 - 9 - 10 - 11 - 12 - 13 - 14 - ...
UCB [BE0003739530/UCB]   
[25/04/2019]

UCB : UCB Media Room: AGM 2019

UCBs General Meeting of ShareholdersFor financial year 2018:Gross dividend of € 1.21 per share 2.5%, payable 30 April 2019All agenda items put to vote approvedBrussels Belgium, 25 April 2019 – 18:00 CEST – regulated information Today, UCB held its Annual General Meeting of Shareholders AGM. At the AGM, 143 259 561 shares 76.07% of shares entitled to vote were represented. During the... See more
 
ECONOCOM GROUP [BE0974266950/ECONB]   
[25/04/2019]

ECONOCOM GROUP : Econocom reports revenue of 623 million euros for the first quarter of 2019, up 3.6%

Q1 2019 revenue Econocom Group's Q1 2019 revenue stands at €623 million, up 3.6% after the application of IFRS16. Organic growth amounted to 1.6%. Technology Management & Financing TMF, the leasing business posted revenue of €221 million, an 11.3% decline. This quarter's performance does not reflect the expected annual trend as the second quarter will benefit from some... See more
 
ECONOCOM GROUP [BE0974266950/ECONB]   
[25/04/2019]

ECONOCOM GROUP : Econocom annonce un chiffre d’affaires de 623 millions d’euros au premier trimestre 2019, en croissance de +3,6%

Chiffre d'affaires du premier trimestre 2019 Le chiffre d'affaires du groupe Econocom s'établit à 623 millions d'euros au T1 2019, en croissance de 3,6 % après application de la norme IFRS16. La croissance organique s'élève à 1,6%. L'activité Technology Management & Financing TMF, activité de location réalise un chiffre d'affaires de 221 millions... See more
 
UCB [BE0003739530/UCB]   
[25/04/2019]

UCB : UCB Media Room: Cimzia at SPIN

New Data Showcases the Value of CIMZIA® certolizumab pegol in Patients with Psoriasis96week safety data from Phase 3 CIMPASI1, CIMPASI2 and CIMPACT studies confirm positive longterm safety profile of CIMZIA® certolizumab pegol in moderatetosevere plaque psoriasisFirst presentation of nail disease data from Phase 3 psoriasis studies demonstrate that 66.2% of patients achieved total resolution of... See more
 
D'IETEREN [BE0974259880/DIE]   
[24/04/2019]

D'IETEREN : Repurchase of own shares in the context of the liquidity contract

PRESS RELEASE: REPURCHASE OF OWN SHARES IN THE CONTEXT OF THE LIQUIDITY CONTRACT REGULATED INFORMATION Wednesday 24 April 2019 – 6:00 pm Repurchase of own shares in the context...